Related Experiment Video
Updated: Aug 22, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Platelet Aggregation Inhibitors and Anticoagulants in Gastroenterological and Visceral Surgical Procedures
Benedikt A Aulinger1, Fuat H Saner, Konstantin Stark
1Department of Internal Medicine II, LMU University Hospital Munich, Germany; Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Germany; Medizinische Klinik und Poliklinik I, University Hospital, LMU Munich, 81377 Munich, Germany.
Insights
Managing patients on antiplatelet or anticoagulant drugs for GI and visceral surgery requires careful consideration of bleeding risk. Most procedures can continue with aspirin, but others may need drug cessation and, rarely, heparin bridging for high thromboembolism risk.
Area of Science:
- Gastroenterology
- Visceral Surgery
- Pharmacology
Background:
- Managing patients on antiplatelet or anticoagulant therapy undergoing gastrointestinal and visceral surgery presents a common clinical challenge.
- Key considerations include procedure-specific hemorrhagic risk, the necessity of anticoagulation, and drug pharmacology.
Approach:
- This review synthesizes information from a targeted PubMed search and relevant specialist society guidelines.
- It provides evidence-based recommendations for managing antithrombotic therapy in surgical patients.
Key Points:
- Monotherapy with aspirin (acetylsalicylic acid) is generally safe for most procedures.
- Other antiplatelet agents (e.g., clopidogrel, prasugrel) and anticoagulants typically do not require interruption for low-risk (<1.5%) endoscopic procedures.
- These medications generally necessitate cessation before high-risk (≥1.5%) gastrointestinal and visceral surgical procedures.
Conclusions:
- Heparin bridging is reserved for patients with a very high risk of thromboembolism (≥5%).
- Understanding current guidelines for managing antithrombotic medications is crucial for clinicians.
- This knowledge facilitates informed decision-making in complex peri-procedural patient management.
Background:
The proper management of patients being treated with platelet aggregation inhibitors or anticoagulant drugs is a common clinical problem for both elective and emergency procedures in gastroenterology and visceral surgery. The essential matters that must be kept in mind in this situation are the hemorrhagic risk of the procedure, the indication for anticoagulation, and the pharmacology of anticoagulant drugs and platelet aggregation inhibitors.
Methods:
This review is based on publications retrieved by a selective search in PubMed and on the guidelines of the relevant specialist societies.
Results:
Nearly all procedures in gastroenterology and visceral surgery can be performed under monotherapy with acetyl - salicylic acid. Other platelet aggregation inhibitors, such as clopidogrel or prasugrel, or anticoagulant drugs generally do not need to paused before diagnostic endoscopic procedures with a low risk of bleeding (<1.5%), but they must be paused before procedures in gastroenterology and visceral surgery where the risk of bleeding is high (≥ 1.5%). Bridging with heparin is reserved for patients with a very high risk of thromboembolism ( ≥ 5%).
Conclusion:
Knowledge of the current recommendations on the management of anticoagulants before gastroenterological and visceral surgical procedures gives the clinician a well-founded means of dealing with this complex and common clinical situation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...